Product Information
IMATINIB MESYLATE 400 MG TAB is a generic product labeled by Upsher-Smith Laboratories LLC, priced at $2.6771 per EA under NDC 00832053303. Its NADAC has been published 104 times since Oct 9, 2024.
FDA first approved this application on Jun 21, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Upsher-Smith Laboratories LLCNDC
00832053303
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IMATINIB MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA212135FDA Approved
6/21/2022
TE Code
AB
On Market Since
5/17/2024
Pharmacological Classes
Price Statistics
The NADAC for IMATINIB MESYLATE 400 MG TAB has been published 104 times since Oct 9, 2024, and over the history we have for it it has risen 29.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6771 per EA |
|---|---|
| All-time high | $3.2150 (Mar 11, 2026) |
| All-time low | $2.0729 (Oct 9, 2024) |
| 52-week high | $3.2150 |
| 52-week low | $2.6771 |
| Median price | $2.8901 |
| Average price | $2.8473 |
| Largest weekly change | +24.0% (Oct 23, 2024) |
| Weeks tracked | 104 |
| Tracking since | Oct 9, 2024 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 24% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Upsher-Smith Laboratories LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
imatinib mesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMATINIB MESYLATE 400 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 400 MG TAB, manufactured by Upsher-Smith Laboratories LLC, is $2.6771 per EA (NDC 00832053303), effective Sep 30, 2026.
How has the price of IMATINIB MESYLATE 400 MG TAB changed over time?
Over the history we have for it, the NADAC for IMATINIB MESYLATE 400 MG TAB has risen 29.1%. It has been tracked across 104 weekly CMS publications since Oct 9, 2024.
What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 400 MG TAB?
Since Oct 9, 2024, the NADAC for IMATINIB MESYLATE 400 MG TAB has ranged from a low of $2.0729 (Oct 9, 2024) to a high of $3.2150 (Mar 11, 2026), with a median of $2.8901 per EA.
Are there cheaper alternatives to IMATINIB MESYLATE 400 MG TAB?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMATINIB MESYLATE 400 MG TAB, is $2.0356 per EA — about 24% below IMATINIB MESYLATE 400 MG TAB.
Who manufactures IMATINIB MESYLATE 400 MG TAB?
IMATINIB MESYLATE 400 MG TAB (NDC 00832053303) is labeled by Upsher-Smith Laboratories LLC, and CMS classifies it as a generic product.